News and Press Releases

RxCelerate acquires cutting-edge molecular
modelling company Prosarix

Cambridge, UK, February 5th 2019 — RxCelerate, one of the leading out-sourced drug discovery and development platforms in the United Kingdom, announced today that it has acquired UK-based molecular modelling company Prosarix. Originally founded in 2006, Prosarix has built a reputation as one of the leading exponents of molecular modelling, supporting both protein engineering and in silico drug design projects.

“The acquisition of Prosarix beautifully complements our existing drug discovery services, including our medicinal chemistry operations based at University of Warwick” said Dr Nigel Ramsden, Executive Vice President, Chemistry, at RxCelerate.

“Prosarix are already well-known to many of our clients” said Dr Jill Reckless, CEO of RxCelerate. “where they have demonstrated over and over again how their proprietary molecular modelling capabilities can discover better molecules than the competition. We are delighted to now have the unique expertise as part of RxCelerate Group.”

“We are very excited to have this opportunity to join a rapidly-expanding, global, quality biotech business, with a unique platform delivering cutting-edge drug discovery and development on an out-sourced basis” said Dr Bill Hamilton, the current Chief Executive at Prosarix, which is currently based just outside Cambridge, UK.

RxCelerate operates a unique model, allowing clients to out-source complete drug discovery and development programs to a team of world-class drug developers obviating the need for internal expertise usually required when out-sourcing to contract research organisations. Founded in 2012, the company initially built its reputation on the quality of its preclinical models of human diseases, but rapidly expanded to offer a comprehensive, turnkey drug discovery and development solution.

“Following the acquisition of bioanalytical CRO Total Scientific and sector-focused back-office service provider The Cambridge Partnership during 2018, this new acquisition underlines our commitment to complete the jigsaw, so that our clients can access world-leading drug discovery capability under one roof” said Founder and Chairman, Dr David Grainger. “Jon Heal and the scientific team at Prosarix are talented modellers, with a proven track-record in molecular design.”

Notes for Editors

About RxCelerate
RxCelerate is an out-sourced drug discovery and development company, founded in Cambridge UK in 2012, with a focus on working smarter. It has grown rapidly to become one of the leading providers of drug development services in the United Kingdom. RxCelerate operates a unique model, providing capabilities to discover and develop drugs for clients, designing as well as executing every aspect of the research and development plan.

RxCelerate offers a wide range of services. The biology team specializes in in vivo pharmacology, offering proprietary models of wide range of human diseases, as well as complex cell-based assays. The chemistry team provides medicinal chemistry, including in silico screening, and synthesis that integrates seamlessly with the in vitro testing capability. A dedicated team designs the optimum discovery or development strategy for each project, as well as integrated program management. By working closely together, these teams can deliver pharma-grade drug product candidates at a fraction of the cost of traditional approaches.

For more information, please visit us at rxcelerate.com and connect with us on Twitter (@RxCelerate). Contact our UK headquarters: jill@rxcelerate.com Tel: +44 (0)1223 804240. Contact our US headquarters: laura@rxcelerate.com Tel: +1 (857) 409-6028

About Prosarix UK Ltd.
Prosarix have been developing and utilising its ProtoDiscovery platform for small molecule design and protein engineering since inception in 2006. Using this technology Prosarix has worked with over 40 companies/organisations, often on multiple projects involving a diverse set of targets and objectives. More recently, Prosarix became a subsidiary of Evolva AG in 2014 before spinning out as an independent company again in 2018.

For more information and contact details, please visit www.prosarix.com or contact Bill Hamilton (bill@rxcelerate.com) Tel: +44 (0)1223 870400.




 

©Prosarix 2007-19 ¦ Newton Hall, Town Street, Newton, Cambridge, CB22 7ZE ¦ +44 (0)1223 870400 ¦ contact@prosarix.com ¦ legal